GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
UK drugmaker GSK presented positive Phase III trial data at the European Geriatric Medicine Society Congress. The trial ...
Pharmaceutical Technology on MSN2d
AstraZeneca’s Fasenra to challenge GSK’s Nucala in rare vasculitis after FDA nodBefore the FDA approved AstraZeneca’s Fasenra, Nucala was the only therapy for treating eosinophilic granulomatosis with ...
GlobalData on MSN3d
MHLW accepts GSK’s multiple myeloma treatment NDA for reviewJapan's MHLW has accepted for review GSK's NDA for Blenrep for patients with relapsed or refractory multiple myeloma.
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
Depemokimab was shown to reduce exacerbations in patients with severe asthma. The proportions of adverse events of ...
GSK announced on Wednesday that it has reached confidential settlements in two lawsuits filed in California State Court ...
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
Until recently, the pharmaceutical industry remained relatively insulated from the simmering trade war between China and the ...
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback